The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.
 
Giulia Maddalena
No Relationships to Disclose
 
Eleonora Perissinotto
No Relationships to Disclose
 
Rossana Intini
No Relationships to Disclose
 
Van Morris
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Incyte; Novartis; Regeneron; Scandion Oncology
Research Funding - Apollo Therapeutics (Inst); Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)
 
Francesca Bergamo
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Pierre Fabre; SERVIER
Speakers' Bureau - Bayer; BMS; Eisai; Lilly; MSD Oncology
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis
 
Timothy Newhook
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Helyon; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis